## VRTX: Vertex Pharmaceuticals Incorpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($435.02)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Voya Investment Management LLC Has $168.85 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251219T135853 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in in Vertex Pharmaceuticals (NASDAQ:VRTX) by 38.2% in Q3, selling 267,387 shares and ending up with 432,257 shares valued at $168.85 million. Despite insider selling totaling $67.33 million, the company exceeded Q3 expectations with an EPS of $4.80 and revenue of $3.08 billion, prompting analysts to maintain a "Moderate Buy" rating with an average target price of $498.42. Institutional investors and hedge funds combined own 90.96% of the company's stock.

**2. Montecito Bank & Trust Buys Shares of 2,239 Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251219T111508 | Somewhat-Bullish | Relevance: 100%
- Montecito Bank & Trust has acquired 2,239 shares of Vertex Pharmaceuticals (VRTX) for approximately $877,000, as disclosed in their recent 13F filing. This comes amidst significant insider selling, with company executives disposing of shares worth millions of dollars. Despite this, analysts maintain a "Moderate Buy" rating for VRTX, which recently surpassed Q3 earnings and revenue expectations.

**3. Thurston Springer Miller Herd & Titak Inc. Sells 2,487 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251218T112553 | Neutral | Relevance: 100%
- Thurston Springer Miller Herd & Titak Inc. significantly reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 91.2% in Q3, selling 2,487 shares and retaining only 240 shares valued at $94,000. This comes alongside substantial insider selling, with executives offloading 151,073 shares worth over $67 million in the past three months. Despite this, Vertex Pharmaceuticals reported strong Q3 earnings, beating analyst estimates for both EPS and revenue, and maintains a "Moderate Buy" consensus rating with an average price target of $498.42.

**4. Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Ipswich Investment Management Co. Inc.**
- Source: MarketBeat | 20251218T135712 | Neutral | Relevance: 100%
- Ipswich Investment Management Co. Inc. significantly reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 62.9% in Q3, selling 3,525 shares and retaining 2,083 shares valued at $816,000. This comes alongside substantial insider selling totaling $67.33 million in the last 90 days, though Wall Street analysts maintain a "Moderate Buy" rating with a consensus price target of $498.42. The company, which develops therapies for cystic fibrosis, recently reported strong Q3 earnings, exceeding analyst expectations for both EPS and revenue.

**5. Corient Private Wealth LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251217T085659 | Somewhat-Bearish | Relevance: 97%
- Corient Private Wealth LLC reduced its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% in the second quarter, selling 3,734 shares and leaving them with 102,816 shares valued at $45.77 million. Other institutional investors also made new investments in VRTX shares, while company insiders, including Chairman Jeffrey M. Leiden and EVP Charles F. Wagner, Jr., sold significant portions of their holdings. Analysts have a "Moderate Buy" rating on Vertex Pharmaceuticals with an average price target of $498.42.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.5x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $117.0B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.5 |
| Current P/E | 24.7 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.3% to 1.5% (-1.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 (-0.4%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.53% (CS: 79) | Neutral |
| RSI_14 | 60.4 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.029x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.034x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $456.20
- **Stop Loss:** $435.02 (4.6% risk)
- **Target:** $477.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $25,547.20
- **Portfolio %:** 25.55%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*